Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Characterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for therapeutic strategy in pancreatic ductal adenocarcinoma (PDAC). Clinico-genomic data for patients with PDAC and other cancers with ATM varian...
Uložené v:
| Vydané v: | Clinical cancer research Ročník 28; číslo 21; s. 4782 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.11.2022
|
| Predmet: | |
| ISSN: | 1557-3265, 1557-3265 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Characterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for therapeutic strategy in pancreatic ductal adenocarcinoma (PDAC).
Clinico-genomic data for patients with PDAC and other cancers with ATM variants were abstracted. Genomic instability scores (GIS) were derived from ATM-mutant cancers and overall survival (OS) was evaluated.
Forty-six patients had PDAC and pathogenic ATM variants including 24 (52%) stage III/IV: gATMm (N = 24), and sATMm (N = 22). Twenty-seven (59%) had biallelic, 15 (33%) monoallelic, and 4 indeterminate (8%) variants. Median OS for advanced-stage cohort at diagnosis (N = 24) was 19.7 months [95% confidence interval (CI): 12.3-not reached (NR)], 27.1 months (95% CI: 22.7-NR) for gATMm (n = 11), and 12.3 months for sATMm (n = 13; 95% CI: 11.9-NR; P = 0.025). GIS was computed for 33 patients with PDAC and compared with other ATM-mutant cancers enriched for HRD. The median was lower (median, 11; range, 2-29) relative to breast (18, 3-55) or ovarian (25, 3-56) ATM-mutant cancers (P < 0.001 and P = 0.003, respectively). Interestingly, biallelic pathogenic ATM variants were mutually exclusive with TP53. Other canonical driver gene (KRAS, CDKN2A, SMAD4) variants were less frequent in ATM-mutant PDAC.
ATM variants in PDAC represent a distinct biologic group and appear to have favorable OS. Nonetheless, pathogenic ATM variants do not confer an HRD signature in PDAC and ATM should be considered as a non-core HR gene in this disease. |
|---|---|
| AbstractList | Characterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for therapeutic strategy in pancreatic ductal adenocarcinoma (PDAC).PURPOSECharacterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for therapeutic strategy in pancreatic ductal adenocarcinoma (PDAC).Clinico-genomic data for patients with PDAC and other cancers with ATM variants were abstracted. Genomic instability scores (GIS) were derived from ATM-mutant cancers and overall survival (OS) was evaluated.EXPERIMENTAL DESIGNClinico-genomic data for patients with PDAC and other cancers with ATM variants were abstracted. Genomic instability scores (GIS) were derived from ATM-mutant cancers and overall survival (OS) was evaluated.Forty-six patients had PDAC and pathogenic ATM variants including 24 (52%) stage III/IV: gATMm (N = 24), and sATMm (N = 22). Twenty-seven (59%) had biallelic, 15 (33%) monoallelic, and 4 indeterminate (8%) variants. Median OS for advanced-stage cohort at diagnosis (N = 24) was 19.7 months [95% confidence interval (CI): 12.3-not reached (NR)], 27.1 months (95% CI: 22.7-NR) for gATMm (n = 11), and 12.3 months for sATMm (n = 13; 95% CI: 11.9-NR; P = 0.025). GIS was computed for 33 patients with PDAC and compared with other ATM-mutant cancers enriched for HRD. The median was lower (median, 11; range, 2-29) relative to breast (18, 3-55) or ovarian (25, 3-56) ATM-mutant cancers (P < 0.001 and P = 0.003, respectively). Interestingly, biallelic pathogenic ATM variants were mutually exclusive with TP53. Other canonical driver gene (KRAS, CDKN2A, SMAD4) variants were less frequent in ATM-mutant PDAC.RESULTSForty-six patients had PDAC and pathogenic ATM variants including 24 (52%) stage III/IV: gATMm (N = 24), and sATMm (N = 22). Twenty-seven (59%) had biallelic, 15 (33%) monoallelic, and 4 indeterminate (8%) variants. Median OS for advanced-stage cohort at diagnosis (N = 24) was 19.7 months [95% confidence interval (CI): 12.3-not reached (NR)], 27.1 months (95% CI: 22.7-NR) for gATMm (n = 11), and 12.3 months for sATMm (n = 13; 95% CI: 11.9-NR; P = 0.025). GIS was computed for 33 patients with PDAC and compared with other ATM-mutant cancers enriched for HRD. The median was lower (median, 11; range, 2-29) relative to breast (18, 3-55) or ovarian (25, 3-56) ATM-mutant cancers (P < 0.001 and P = 0.003, respectively). Interestingly, biallelic pathogenic ATM variants were mutually exclusive with TP53. Other canonical driver gene (KRAS, CDKN2A, SMAD4) variants were less frequent in ATM-mutant PDAC.ATM variants in PDAC represent a distinct biologic group and appear to have favorable OS. Nonetheless, pathogenic ATM variants do not confer an HRD signature in PDAC and ATM should be considered as a non-core HR gene in this disease.CONCLUSIONSATM variants in PDAC represent a distinct biologic group and appear to have favorable OS. Nonetheless, pathogenic ATM variants do not confer an HRD signature in PDAC and ATM should be considered as a non-core HR gene in this disease. Characterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for therapeutic strategy in pancreatic ductal adenocarcinoma (PDAC). Clinico-genomic data for patients with PDAC and other cancers with ATM variants were abstracted. Genomic instability scores (GIS) were derived from ATM-mutant cancers and overall survival (OS) was evaluated. Forty-six patients had PDAC and pathogenic ATM variants including 24 (52%) stage III/IV: gATMm (N = 24), and sATMm (N = 22). Twenty-seven (59%) had biallelic, 15 (33%) monoallelic, and 4 indeterminate (8%) variants. Median OS for advanced-stage cohort at diagnosis (N = 24) was 19.7 months [95% confidence interval (CI): 12.3-not reached (NR)], 27.1 months (95% CI: 22.7-NR) for gATMm (n = 11), and 12.3 months for sATMm (n = 13; 95% CI: 11.9-NR; P = 0.025). GIS was computed for 33 patients with PDAC and compared with other ATM-mutant cancers enriched for HRD. The median was lower (median, 11; range, 2-29) relative to breast (18, 3-55) or ovarian (25, 3-56) ATM-mutant cancers (P < 0.001 and P = 0.003, respectively). Interestingly, biallelic pathogenic ATM variants were mutually exclusive with TP53. Other canonical driver gene (KRAS, CDKN2A, SMAD4) variants were less frequent in ATM-mutant PDAC. ATM variants in PDAC represent a distinct biologic group and appear to have favorable OS. Nonetheless, pathogenic ATM variants do not confer an HRD signature in PDAC and ATM should be considered as a non-core HR gene in this disease. |
| Author | Bandlamudi, Chaitanya Capanu, Marinela O'Connor, Catherine A Keane, Fergus Iacobuzio-Donahue, Christine Kelsen, David P O'Reilly, Eileen M Umeda, Shigeaki Yu, Kenneth H Forman, Daniella Crane, Christopher Varghese, Anna M Reyngold, Marsha Park, Wungki Chou, Joanne F Balogun, Fiyinfolu |
| Author_xml | – sequence: 1 givenname: Wungki orcidid: 0000-0002-8006-3102 surname: Park fullname: Park, Wungki organization: David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 2 givenname: Catherine A orcidid: 0000-0003-4080-9149 surname: O'Connor fullname: O'Connor, Catherine A organization: Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 3 givenname: Chaitanya orcidid: 0000-0003-1108-4919 surname: Bandlamudi fullname: Bandlamudi, Chaitanya organization: Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 4 givenname: Daniella orcidid: 0000-0002-2712-9352 surname: Forman fullname: Forman, Daniella organization: Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 5 givenname: Joanne F orcidid: 0000-0002-6866-2022 surname: Chou fullname: Chou, Joanne F organization: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 6 givenname: Shigeaki orcidid: 0000-0001-5693-1515 surname: Umeda fullname: Umeda, Shigeaki organization: Human Oncology Pathogenesis Program, Sloan Kettering Institute, New York, New York – sequence: 7 givenname: Marsha orcidid: 0000-0001-9475-146X surname: Reyngold fullname: Reyngold, Marsha organization: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 8 givenname: Anna M orcidid: 0000-0001-5426-0885 surname: Varghese fullname: Varghese, Anna M organization: David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 9 givenname: Fergus orcidid: 0000-0001-6651-2090 surname: Keane fullname: Keane, Fergus organization: David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 10 givenname: Fiyinfolu orcidid: 0000-0003-4703-1560 surname: Balogun fullname: Balogun, Fiyinfolu organization: David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 11 givenname: Kenneth H orcidid: 0000-0002-4774-2672 surname: Yu fullname: Yu, Kenneth H organization: David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 12 givenname: David P orcidid: 0000-0001-6139-438X surname: Kelsen fullname: Kelsen, David P organization: David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 13 givenname: Christopher orcidid: 0000-0001-5143-2784 surname: Crane fullname: Crane, Christopher organization: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 14 givenname: Marinela orcidid: 0000-0003-4953-3193 surname: Capanu fullname: Capanu, Marinela organization: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York – sequence: 15 givenname: Christine orcidid: 0000-0002-4672-3023 surname: Iacobuzio-Donahue fullname: Iacobuzio-Donahue, Christine organization: Human Oncology Pathogenesis Program, Sloan Kettering Institute, New York, New York – sequence: 16 givenname: Eileen M orcidid: 0000-0002-8076-9199 surname: O'Reilly fullname: O'Reilly, Eileen M organization: David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36040493$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkLtOwzAYRi1URC_wCCCPLAHfk7BV4VKkIqqqbEiR4_wGo8QOTjrA01PUIjF9Zzg6wzdFIx88IHROyRWlMrumJM0SIji7Kop1wlhCRcaP0IRKmSacKTn6x2M07fsPQqigRJygMVdEEJHzCXotGuedCckb-NA6g4t3HbUZILpvPbjgcbB4vnnC2td4sb7FzuOV9iaC7nGxA4g3eN51jTN73YaIV78FZ-AUHVvd9HB22Bl6ub_bFItk-fzwWMyXiRGUDomRDKjJJBWQUoAsU1VNuM61pZwoomRVEVYD2NTmRIpcp7kCMMxSpbgVhM3Q5b7bxfC5hX4oW9cbaBrtIWz7kqUkYzJPJdupFwd1W7VQl110rY5f5d8j7AfXTmR0 |
| CitedBy_id | crossref_primary_10_1016_j_drup_2025_101291 crossref_primary_10_1177_17562848231171456 crossref_primary_10_4251_wjgo_v16_i11_4489 crossref_primary_10_3390_cancers14246223 crossref_primary_10_1016_j_ejca_2024_114226 crossref_primary_10_1245_s10434_024_16331_4 crossref_primary_10_3390_cancers15112955 crossref_primary_10_1002_path_6136 crossref_primary_10_1002_cam4_70393 crossref_primary_10_1053_j_seminoncol_2023_11_001 crossref_primary_10_1093_oncolo_oyaf141 crossref_primary_10_1016_j_cell_2023_02_014 crossref_primary_10_1016_j_gim_2024_101243 crossref_primary_10_1186_s12967_024_05227_2 crossref_primary_10_1016_j_ctrv_2023_102650 crossref_primary_10_1038_s41575_023_00840_w crossref_primary_10_1016_j_pan_2023_10_017 crossref_primary_10_1016_j_hoc_2024_01_006 crossref_primary_10_1038_s41591_024_03362_3 |
| ContentType | Journal Article |
| Copyright | 2022 American Association for Cancer Research. |
| Copyright_xml | – notice: 2022 American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1078-0432.CCR-22-1483 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-3265 |
| ExternalDocumentID | 36040493 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: K12 CA184746 – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 IH2 KQ8 L7B LSO NPM OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV 7X8 |
| ID | FETCH-LOGICAL-c411t-c52e1c8514e71ee886bd03a9af1306065bb02deef7f90549a796eec2f1663f402 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 26 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000884827000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1557-3265 |
| IngestDate | Thu Oct 02 11:40:24 EDT 2025 Mon Jul 21 06:04:47 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 21 |
| Language | English |
| License | 2022 American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c411t-c52e1c8514e71ee886bd03a9af1306065bb02deef7f90549a796eec2f1663f402 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-4774-2672 0000-0003-4080-9149 0000-0001-5426-0885 0000-0002-2712-9352 0000-0001-5143-2784 0000-0002-8006-3102 0000-0002-4672-3023 0000-0001-6651-2090 0000-0003-1108-4919 0000-0001-5693-1515 0000-0001-9475-146X 0000-0003-4703-1560 0000-0002-8076-9199 0000-0002-6866-2022 0000-0003-4953-3193 0000-0001-6139-438X |
| OpenAccessLink | https://aacrjournals.org/clincancerres/article-pdf/28/21/4782/3214327/4782.pdf |
| PMID | 36040493 |
| PQID | 2708259752 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2708259752 pubmed_primary_36040493 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-11-01 20221101 |
| PublicationDateYYYYMMDD | 2022-11-01 |
| PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical cancer research |
| PublicationTitleAlternate | Clin Cancer Res |
| PublicationYear | 2022 |
| SSID | ssj0014104 |
| Score | 2.5224485 |
| Snippet | Characterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 4782 |
| SubjectTerms | Ataxia Telangiectasia Mutated Proteins - genetics Carcinoma, Pancreatic Ductal - pathology Cohort Studies Genomics Humans Pancreatic Neoplasms Pancreatic Neoplasms - pathology |
| Title | Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36040493 https://www.proquest.com/docview/2708259752 |
| Volume | 28 |
| WOSCitedRecordID | wos000884827000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEbxGm8duNl6krJZeWpZSoQdhyWYT6MHd2lZ_v5PdrT0Jgpe9BZbwZeb7MplvELrzDi_cKkpcIDsE8q0gijlBhMxpZLRjRkfVsAk5HEaTiUqaC7dF86xyFROrQJ2Xxt-RPzDpxYySAXuafRA_NcpXV5sRGpuoxYHKeFTLybqKIGg1PhBSJhwkFgZNBw8NIggW3llWcHYfxyMCggxkAf-dZVbZprf_3_88QHsNz8TdGhiHaMMWR2hn0FTSj9FbbQhaEm_S-j41OP5xbq4bM3HpcHc8wLrIcX_0jKcFTgAh_g07jj1U5o-4u65-YyC_OGlark7Qa-9lHPdJM2mBGEHpkpiAWWqAfAkrqbVRFGZ5h2ulHaQ4kDhBlnVYbq2TTgHHU1qq0FrDHAXC4kCCnqKtoizsOcLKC6yIU8ZMLqhxGc25tt5TyESOZbaNblf7lgKSfXlCF7b8XKTrnWujs3rz01ltuZHyEIKNUPziD6sv0S7zPQpVw-AVajk4x_YabZuv5XQxv6kgAt9hMvgGS8bDBQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinico-genomic+Characterization+of+ATM+and+HRD+in+Pancreas+Cancer%3A+Application+for+Practice&rft.jtitle=Clinical+cancer+research&rft.au=Park%2C+Wungki&rft.au=O%27Connor%2C+Catherine+A&rft.au=Bandlamudi%2C+Chaitanya&rft.au=Forman%2C+Daniella&rft.date=2022-11-01&rft.eissn=1557-3265&rft.volume=28&rft.issue=21&rft.spage=4782&rft_id=info:doi/10.1158%2F1078-0432.CCR-22-1483&rft_id=info%3Apmid%2F36040493&rft_id=info%3Apmid%2F36040493&rft.externalDocID=36040493 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-3265&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-3265&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-3265&client=summon |